JP2002535371A - リバビリンによる免疫応答の調節 - Google Patents

リバビリンによる免疫応答の調節

Info

Publication number
JP2002535371A
JP2002535371A JP2000595690A JP2000595690A JP2002535371A JP 2002535371 A JP2002535371 A JP 2002535371A JP 2000595690 A JP2000595690 A JP 2000595690A JP 2000595690 A JP2000595690 A JP 2000595690A JP 2002535371 A JP2002535371 A JP 2002535371A
Authority
JP
Japan
Prior art keywords
challenge
nucleoside
ribavirin
immune system
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000595690A
Other languages
English (en)
Japanese (ja)
Inventor
タム，ロバート
Original Assignee
アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド filed Critical アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド
Publication of JP2002535371A publication Critical patent/JP2002535371A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
JP2000595690A 1999-01-29 1999-12-20 リバビリンによる免疫応答の調節 Withdrawn JP2002535371A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24136799A 1999-01-29 1999-01-29
US09/241,367 1999-01-29
PCT/US1999/030490 WO2000044388A1 (en) 1999-01-29 1999-12-20 Modulation of immune response by ribavirin

Publications (1)

Publication Number Publication Date
JP2002535371A true JP2002535371A (ja) 2002-10-22

Family

ID=22910442

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000595690A Withdrawn JP2002535371A (ja) 1999-01-29 1999-12-20 リバビリンによる免疫応答の調節

Country Status (20)

Country Link
EP (1) EP1146883A4 (xx)
JP (1) JP2002535371A (xx)
KR (1) KR20020023939A (xx)
CN (1) CN1334736A (xx)
AU (1) AU2483300A (xx)
BR (1) BR9917090A (xx)
CA (1) CA2357735A1 (xx)
CZ (1) CZ20012519A3 (xx)
HK (1) HK1040937A1 (xx)
HR (1) HRP20010496A2 (xx)
HU (1) HUP0200027A2 (xx)
IL (1) IL144130A0 (xx)
MX (1) MXPA01007211A (xx)
NO (1) NO20013529L (xx)
PL (1) PL364699A1 (xx)
RU (1) RU2211698C2 (xx)
SI (1) SI20802A (xx)
SK (1) SK10092001A3 (xx)
WO (1) WO2000044388A1 (xx)
ZA (1) ZA200105595B (xx)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009529543A (ja) * 2006-03-14 2009-08-20 ホールサム バイオファーム ピーティーワイ エルティーディー アレルギー性疾患を治療するための方法および組成物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022830B2 (en) 2000-08-17 2006-04-04 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US6858590B2 (en) 2000-08-17 2005-02-22 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US6680059B2 (en) 2000-08-29 2004-01-20 Tripep Ab Vaccines containing ribavirin and methods of use thereof
WO2002014362A2 (en) 2000-08-17 2002-02-21 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
WO2009022236A2 (en) 2007-08-16 2009-02-19 Tripep Ab Immunogen platform

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
EP0038629A1 (en) * 1980-04-17 1981-10-28 Beecham Group Plc Virazole derivatives, process for their preparation and use as antiviral agents
BE902199A (fr) * 1984-10-29 1985-07-31 Vira Tek Inc Procede de traitement medical de maladies virales utilisant le 1-beta-d-ribofurannosyl-1, 2,4-triazole-3-carboxamide.
EP0262125B1 (en) * 1986-03-27 1996-03-27 Gensia, Inc. AICA riboside for the prophylactic treatment of diseases with restricted blood flow.
US5030623A (en) * 1986-03-27 1991-07-09 The Regents Of The University Of California Methods for increasing extracellular adenosine and for stabilizing mast cells
US5767097A (en) * 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
BR9707154A (pt) * 1996-01-23 1999-05-25 Icn Pharmaceuticals Modulaç o da express o de citocina em th1/th2 por ribavirina e análogos de ribavirina em linfócitos t ativados
SK284054B6 (sk) * 1996-10-16 2004-08-03 Icn Pharmaceuticals, Inc. Substituované triazolové nukleozidy, farmaceutický prostriedok s ich obsahom a ich použitie

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009529543A (ja) * 2006-03-14 2009-08-20 ホールサム バイオファーム ピーティーワイ エルティーディー アレルギー性疾患を治療するための方法および組成物

Also Published As

Publication number Publication date
HUP0200027A2 (en) 2002-04-29
BR9917090A (pt) 2001-10-16
CN1334736A (zh) 2002-02-06
WO2000044388A1 (en) 2000-08-03
CA2357735A1 (en) 2000-08-03
RU2211698C2 (ru) 2003-09-10
NO20013529D0 (no) 2001-07-17
SI20802A (sl) 2002-08-31
HK1040937A1 (zh) 2002-06-28
ZA200105595B (en) 2002-10-07
AU2483300A (en) 2000-08-18
CZ20012519A3 (cs) 2002-05-15
IL144130A0 (en) 2002-05-23
PL364699A1 (en) 2004-12-13
HRP20010496A2 (en) 2003-08-31
EP1146883A1 (en) 2001-10-24
KR20020023939A (ko) 2002-03-29
SK10092001A3 (sk) 2002-02-05
EP1146883A4 (en) 2004-11-24
NO20013529L (no) 2001-09-12
MXPA01007211A (es) 2002-05-06

Similar Documents

Publication Publication Date Title
US6815542B2 (en) Nucleoside compounds and uses thereof
KR960007532B1 (ko) 1,3-옥사티오란 뉴클레오시드 동족체
US11364257B2 (en) Phosphoramidates for the treatment of hepatitis B virus
CN1268335C (zh) 具有甲脒修饰的单环碱基的核苷类似物
AU669702B2 (en) Enantiomeric hydroxylated xanthine compounds
US6525033B1 (en) Nucleosides with anti-hepatitis B virus activity
CN101980707A (zh) 新的取代的咪唑并喹啉化合物
JP2018500334A (ja) Ｂ型肝炎ウイルスの治療のためのホスホルアミデート
KR20030032927A (ko) 뉴클레오시드 화합물 및 이들의 용도
US6423695B1 (en) Cytokine related treatments of disease
US20020187945A1 (en) Modulation of immune response by ribavirin
TW202120103A (zh) 奈米粒子組合物
JP2002535371A (ja) リバビリンによる免疫応答の調節
AU732120B2 (en) Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
US20020156030A1 (en) Heterocyclic aromatic compounds and uses thereof
US20110071202A1 (en) Anti-hepatitis c virus agents and anti-hiv agents
CN106928298B (zh) 环二核苷酸cGAMP衍生物的结构组成、制备方法及其在抗肿瘤中的应用
AU2001292557A1 (en) Methods of drug delivery to hepatocytes and treatment of flaviviridae infections
Pawlowska et al. Nucleoside and nucleotide analogues as potential therapeutics
NZ512879A (en) Modulation of immune response by Ribavirin
JP2799368B2 (ja) 抗原虫剤
FR3110836A1 (fr) Utilisation de NMN pour réduire l’immunodépression et l’immunosénescence
CN1817349A (zh) 具有甲脒修饰的单环碱基的核苷类似物
JPS63284129A (ja) Ｂ型肝炎ウイルス抑制剤
JPH107556A (ja) 細胞接着抑制剤

Legal Events

Date Code Title Description
A300 Application deemed to be withdrawn because no request for examination was validly filed

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20070306